This index catalogs animal models and experimental model systems used in neurodegenerative disease research. These models are essential for understanding disease mechanisms, testing therapeutic interventions, and translating findings from basic science to clinical applications.
Model systems span multiple species from invertebrates (C. elegans, Drosophila) to mammals (mice, rats, non-human primates), each offering distinct advantages for studying specific aspects of neurodegeneration.
Alzheimer's Disease Models
flowchart TD
models["Models"]
style models fill:#4fc3f7,stroke:#333,color:#000
models_0["Alzheimers Disease Models"]
models -->|"includes"| models_0
style models_0 fill:#81c784,stroke:#333,color:#000
models_1["5xFAD Transgenic Mouse Model"]
models -->|"includes"| models_1
style models_1 fill:#ef5350,stroke:#333,color:#000
models_2["APP/PS1 Dual Transgenic Model"]
models -->|"includes"| models_2
style models_2 fill:#ffd54f,stroke:#333,color:#000
models_3["Cerebral Organoid Model"]
models -->|"includes"| models_3
style models_3 fill:#ce93d8,stroke:#333,color:#000
models_4["Parkinsons Disease Models"]
models -->|"includes"| models_4
style models_4 fill:#4fc3f7,stroke:#333,color:#000
models_5["6-OHDA Rat Model"]
models -->|"includes"| models_5
style models_5 fill:#81c784,stroke:#333,color:#000
5xFAD Transgenic Mouse Model The 5xFAD model expresses five familial AD mutations (3 APP + 2 PSEN1), producing aggressive amyloid-beta pathology from 2 months of age.
... This index catalogs animal models and experimental model systems used in neurodegenerative disease research. These models are essential for understanding disease mechanisms, testing therapeutic interventions, and translating findings from basic science to clinical applications.
Model systems span multiple species from invertebrates (C. elegans, Drosophila) to mammals (mice, rats, non-human primates), each offering distinct advantages for studying specific aspects of neurodegeneration.
Alzheimer's Disease Models
Mermaid diagram (expand to render)
5xFAD Transgenic Mouse Model The 5xFAD model expresses five familial AD mutations (3 APP + 2 PSEN1), producing aggressive amyloid-beta pathology from 2 months of age.
[5xFAD Transgenic Mouse Model](/models/5xfad-transgenic-mouse-model)
Mechanism: 5 mutations drive rapid Aβ42 production and aggregation
Applications: Anti-amyloid therapy testing, amyloid cascade studies
APP/PS1 Dual Transgenic Model The APP/PS1 model expresses mutant APP (Swedish) and PSEN1 (M146L), producing amyloid plaques from 6 months.
[APP/PS1 Dual Transgenic Model](/models/app-ps1-dual-transgenic-model)
Mechanism: Increased Aβ production, shifted to Aβ42 species
Applications: Immunotherapy testing, biomarker validation
Cerebral Organoid Model Cerebral organoids are 3D brain tissue cultures derived from stem cells, providing human models for AD and PD.
[Cerebral Organoid Model](/models/cerebral-organoid-model)
Mechanism: Self-organizing brain tissue recapitulates development
Applications: Disease modeling, drug testing, mechanism studies
Parkinson's Disease Models
6-OHDA Rat Model The 6-hydroxydopamine (6-OHDA) rat model replicates selective dopaminergic degeneration via oxidative stress.
[6-OHDA Rat Model of Parkinson's Disease](/models/6-ohda-rat-model-parkinsons)
Mechanism: 6-OHDA uptake via dopamine transporters causes oxidative stress
Applications: Testing dopaminergic medications, cell transplantation
MPTP Mouse Model MPTP is a neurotoxin that selectively destroys dopaminergic neurons via mitochondrial complex I inhibition.
[MPTP Mouse Model of Parkinson's Disease](/models/mptp-mouse-model-parkinsons)
Mechanism: MPTP metabolized to MPP+, inhibits complex I
Applications: Neuroprotection, mitochondrial dysfunction studies
Alpha-Synuclein Transgenic Models Transgenic models expressing mutant alpha-synuclein (A53T, A30P) recapitulate Lewy body formation.
[A53T Alpha-Synuclein Transgenic Mouse Model](/models/a53t-alpha-synuclein-mouse-parkinsons)
Mechanism: Mutant α-synuclein promotes aggregation
Applications: Anti-aggregation therapies, Lewy body studies
[A30P Alpha-Synuclein Transgenic Mouse Model](/models/a30p-alpha-synuclein-mouse-model)
Mechanism: A30P mutation accelerates aggregation
Applications: Aggregation mechanism studies
Alpha-Synuclein PFF Model The PFF model uses synthetic preformed fibrils to induce endogenous α-synuclein aggregation.
[Alpha-Synuclein PFF Model](/models/alpha-synuclein-pff-model)
Mechanism: Prion-like seeding of endogenous α-synuclein
Applications: Propagation studies, immunotherapy testing
LRRK2 Models LRRK2 transgenic models express the G2019S mutation, the most common familial PD variant.
[LRRK2 G2019S Transgenic Mouse Model](/models/lrrk2-g2019s-transgenic-mouse-model)
Mechanism: Kinase hyperactivation (2-3x)
Applications: LRRK2 kinase inhibitor testing
[AAV-LRRK2 Gene Delivery Model](/models/aav-lrrk2-gene-delivery-model)
Mechanism: Viral vector-mediated LRRK2 overexpression
Applications: Regional overexpression, dose control
MitoPark Mouse Model MitoPark uses tissue-specific Parkin deletion to model mitochondrial dysfunction in PD.
[MitoPark Mouse Model](/models/mitopark-mouse-model)
Mechanism: Impaired mitophagy leads to mitochondrial dysfunction
Applications: Mitophagy enhancers, mitochondrial protectants
Rotenone-Induced Parkinsonism Model Rotenone is a complex I inhibitor that reproduces mitochondrial dysfunction and α-synuclein pathology.
[Rotenone-Induced Parkinsonism Model](/models/rotenone-parkinsonism-model)
Mechanism: Chronic complex I inhibition
Applications: Mitochondrial therapies, neuroprotection
Human Cell Models
iPSC-Derived Dopaminergic Neurons Induced pluripotent stem cell-derived neurons provide patient-specific disease modeling.
[iPSC-Derived Dopaminergic Neurons](/models/ipsc-derived-dopaminergic-neurons)
Mechanism: Patient-derived neurons reveal disease phenotypes
Applications: Drug screening, personalized medicine
All Model Pages (13 total) | Model | Disease | Species | Key Applications |
[Experiments](/experiments) — Experimental methods and protocols
[Therapeutics](/therapeutics) — Therapeutic interventions tested in models
[Mechanisms](/mechanisms) — Disease mechanisms studied in model systems
Page Count Total: 15 model pages
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
[TREM2-Dependent Microglial Senescence Transition](/hypothesis/h-61196ade) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: TREM2
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7
[SASP-Mediated Complement Cascade Amplification](/hypothesis/h-58e4635a) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: C1Q/C3
Related Analyses:
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data)](/analysis/SDA-2026-04-02-gap-seaad-v4-20260402065846) 🔄
[SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) 🔄
Show full description